Dexamethasone

Lekthasone should be administered intravenously or intramuscularly in an emergency and in case of impossibility of oral administration.

Endocrine system diseases:

• replacement therapy of primary or secondary (pituitary) failure of the adrenal glands (except for acute adrenal insufficiency glands in which hydrocortisone or cortisone are more suitable, given their more pronounced hormonal effect);
• acute adrenal gland insufficiency (hydrocortisone or cortisone are the drugs of choice, it may be necessary to use simultaneous mineralocorticoids, especially in the case of synthetic analogues);
• before surgery and in cases of serious injury or illness in patients with established adrenal insufficiency or when adrenocortical reserve is uncertain;
• shock resistant to conventional therapy, while existing or suspected failure of the adrenal glands;
• congenital hyperplasia of adrenal glands;
• purulent inflammation of the thyroid gland and severe forms of radiation thyroiditis.

rheumatic diseases:
(As adjuvant therapy at the time when the base treatment had no effect, that is, patients who have analgesic and anti-inflammatory activity of NSAIDs been unsatisfactory):

• rheumatoid arthritis, including juvenile rheumatoid arthritis, extra-articular manifestations of rheumatoid arthritis (rheumatoid light, changes in the heart, eyes, cutaneous vasculitis);
• synovitis in osteoarthritis, post-traumatic osteoarthritis; epicondylitis, acute nonspecific tenosynovitis; acute gouty arthritis; psoriatic arthritis; ankylosing spondylitis; systemic connective tissue disease; vasculitis.

Skin diseases:

• pemphigus; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; bullous dermatitis herpetiformis; severe erythema; erythema nodosum; severe seborrheic dermatitis; severe psoriasis; urticaria that does not respond to standard treatment; mycosis fungoides; dermatomyositis.

Allergic diseases:
(Not amenable to traditional treatment)

• bronchial asthma; contact dermatitis; atopic dermatitis; serum sickness; chronic or seasonal allergic rhinitis; allergies to medicines; urticaria after the transfusion.
  
  

Diseases of visual organs:

• inflammatory diseases of the eye (sharp central choroiditis, optic neuritis); allergic diseases (conjunctivitis, uveitis, sclerites, keratitis, iritis); immune system disease (sarcoidosis, temporal arteritis); proliferative changes in the orbit (endocrine ophthalmopathy, pseudotumor); immunosuppressive therapy for corneal transplantation.

The solution may be administered systemically or locally (injection under the conjunctiva and retrobulbar or parabulbarno administration).

Gastrointestinal disorders:
to remove the patient from the critical state with:

• ulcerative colitis (severe development); Crohn's disease (heavy development); chronic autoimmune hepatitis; a reaction of rejection in liver transplantation.

Diseases of the respiratory tract:

• symptomatic sarcoidosis (symptomatic); acute toxic bronchiolitis; chronic bronchitis and asthma (during exacerbation); focal or disseminated pulmonary tuberculosis (TB with appropriate therapy); berylliosis (granulomatous inflammation); radiation or aspiration pneumonitis.

Hematologic Disorders:

• acquired or congenital chronic aplastic anemia; autoimmune hemolytic anemia; secondary thrombocytopenia in adults; erythroblastopenia; Acute lymphoblastic leukemia (induction therapy); idiopathic thrombocytopenic purpura in adults (only intravenous - intramuscular administration is contraindicated).

Kidney diseases:

• immunosuppressive therapy in kidney transplantation; stimulating diuresis or decrease proteinuria in idiopathic nephrotic syndrome (without uremia) and renal dysfunction in systemic lupus erythematosus.

Malignant cancer deceases:

• palliation of leukemia and lymphomas in adults; acute leukemia in children; hypercalcaemia in malignant diseases.

Swelling of the brain:

• cerebral edema due to primary or metastatic brain tumor, craniotomy, and traumatic brain injury.

Shock:

• shock, which does not respond to standard treatment; shock in patients with adrenal insufficiency of the cortex; anaphylactic shock (intravenously after administration of epinephrine), before surgery to prevent shock in cases of suspected or established insufficiency adrenal cortex glands.

Other indications:

• tuberculous meningitis with subarachnoid blockade (with appropriate anti-tuberculosis therapy); trichinosis with neurological symptoms of trichinosis or infarction; cystic tumor aponeurosis or tendon (ganglia).

Indications for intraarticular injection or injection into soft tissues:

• Rheumatoid arthritis (severe inflammation of the joint individual); ankylosing spondylitis (when the inflamed joints are not amenable to traditional treatment); psoriatic arthritis (oligoarticular form and tenosynovitis); monoartrit (after the evacuation of the synovial fluid); osteoarthritis joints (only in case exudate and synovitis); vnesusgavnoy rheumatism (epicondylitis, tendonitis, bursitis); and acute gouty arthritis.

Local administration (injection into the lesion site):

• keloid lesion; hypertrophic, infiltrated, inflammatory lesions of herpes, psoriasis, annular granuloma, sclerosing folliculitis, discoid lupus and cutaneous sarcoidosis; disc red wolf lichen; Urbach-Oppenheim disease; localized alopecia.